Analytical Method Development: SOP for Analytical Method for Creams and Gels – V 2.0
Standard Operating Procedure for Analytical Method Development for Cream and Gel Formulations
| Department |
Analytical Method Development |
| SOP No. |
SOP/AMD/165/2025 |
| Supersedes |
SOP/AMD/165/2022 |
| Page No. |
Page 1 of 14 |
| Issue Date |
19/05/2025 |
| Effective Date |
20/05/2025 |
| Review Date |
19/05/2026 |
1. Purpose
To define the procedure for developing and validating analytical methods for pharmaceutical creams and gels, including assay, content uniformity, viscosity, pH, drug release, and physical
stability to ensure product quality and regulatory compliance.
2. Scope
This SOP is applicable to the Analytical Method Development (AMD) department for semi-solid dosage forms such as creams and gels intended for topical or transdermal delivery, including ANDA/NDA submission batches and commercial scale-up formulations.
3. Responsibilities
- Analytical Scientist: Develops analytical methods based on formulation composition and tests them for specificity, accuracy, and reproducibility.
- Formulation Scientist: Shares formulation attributes, target strength, and performance expectations.
- QA Officer: Ensures adherence to GMP, reviews method validation reports, and oversees compliance documentation.
- Head – AMD: Provides final approval for validated methods and ensures method transfer readiness.
4. Accountability
The Head of Analytical Method Development is accountable for the scientific justification, validation compliance, and documentation accuracy of all methods developed for cream and gel formulations.
5. Procedure
5.1 Understanding Formulation Matrix
- Obtain details of the active ingredient (API) solubility, excipients used (gelling agents, emollients, surfactants), and intended dosage form (cream or gel).
- Classify the formulation as oil-in-water (O/W) cream, water-in-oil (W/O) cream, or hydrogel for method optimization.
5.2 Assay and Content Uniformity
- Accurately weigh the sample and dilute with a suitable solvent (e.g., ethanol, methanol).
- If insoluble components are present, centrifuge or filter the sample before analysis.
- Analyze using validated HPLC or UV spectrophotometry.
- Acceptance Criteria: 95.0%–105.0% of label claim with %RSD ≤ 2.0% for multiple samples.
- Log data in Annexure-1: Assay Log Sheet.
5.3 Viscosity Measurement
- Use a Brookfield viscometer with suitable spindle (e.g., LV-3, LV-4) depending on viscosity range.
- Maintain sample at 25 ± 2°C during testing.
- Record values at multiple RPMs and calculate average viscosity.
- Document in Annexure-2: Viscosity Data Sheet.
5.4 pH Determination
- Disperse approximately 1 g of cream/gel in 10 mL of distilled water and mix thoroughly.
- Measure pH using a calibrated pH meter at room temperature.
- Acceptance: pH 4.0–7.5 depending on formulation type.
5.5 In-Vitro Release Testing (IVRT)
- Use Franz diffusion cells with synthetic membranes (e.g., cellulose acetate or Strat-M).
- Apply ~300 mg of sample in the donor compartment and use receptor medium (e.g., PBS pH 7.4) in the receptor chamber.
- Maintain temperature at 32 ± 1°C and stir continuously.
- Withdraw receptor samples at 1, 2, 4, 6, and 8 hours; analyze via HPLC.
- Plot cumulative drug release and determine release rate (µg/cm²/h).
- Log in Annexure-3: IVRT Profile Sheet.
5.6 Physical and Chemical Stability
- Store samples at 25°C/60% RH and 40°C/75% RH.
- Evaluate at Day 0, 15, 30, 60, 90 for:
- Color, odor, phase separation
- Assay and pH
- Drug release performance
- Document in Annexure-4: Stability Monitoring Log.
5.7 Method Validation
- Validate assay and IVRT methods as per ICH Q2(R2):
- Parameters:
- Specificity
- Linearity (R² ≥ 0.999)
- Accuracy (98%–102%)
- Precision (%RSD ≤ 2%)
- Robustness
- Summarize in Annexure-5: Method Validation Report.
6. Abbreviations
- IVRT: In-Vitro Release Testing
- HPLC: High Performance Liquid Chromatography
- RSD: Relative Standard Deviation
- RH: Relative Humidity
- SOP: Standard Operating Procedure
7. Documents
- Assay Log Sheet – Annexure-1
- Viscosity Data Sheet – Annexure-2
- IVRT Profile Sheet – Annexure-3
- Stability Monitoring Log – Annexure-4
- Method Validation Report – Annexure-5
8. References
- ICH Q2(R2) – Validation of Analytical Procedures
- FDA Guidance on Topical Product Performance Testing
- USP <1724> – Semisolid Drug Products
- WHO Guidelines on Stability Testing of Pharmaceutical Products
9. SOP Version
Version: 2.0
10. Approval Section
|
Prepared By |
Checked By |
Approved By |
| Signature |
|
|
|
| Date |
|
|
|
| Name |
|
|
|
| Designation |
|
|
|
| Department |
|
|
|
11. Annexures
Annexure-1: Assay Log Sheet
| Sample ID |
Assay (%) |
% RSD |
Analyst |
| CRG/2025/017 |
99.3% |
1.4% |
Sunita Reddy |
Annexure-2: Viscosity Data Sheet
| Sample ID |
Spindle |
RPM |
Viscosity (cP) |
Analyst |
| GEL/2025/004 |
LV-3 |
30 |
3500 |
Rajesh Kumar |
Annexure-3: IVRT Profile Sheet
| Time (hr) |
Drug Released (µg/cm²) |
Analyst |
| 1 |
15.2 |
Ajay Verma |
| 2 |
28.5 |
Ajay Verma |
| 4 |
52.9 |
Ajay Verma |
Annexure-4: Stability Monitoring Log
| Time Point |
Condition |
Observation |
Analyst |
| 30 Days |
40°C/75% RH |
No change in color or phase |
Sunita Reddy |
Annexure-5: Method Validation Report
| Parameter |
Result |
Acceptance |
Status |
| Linearity |
R² = 0.9994 |
≥ 0.999 |
Pass |
| Accuracy |
98.7%–101.4% |
98%–102% |
Pass |
Revision History:
| Revision Date |
Revision No. |
Details |
Reason |
Approved By |
| 04/05/2025 |
2.0 |
Included IVRT and validation annexures |
Annual SOP Review |
|